View Older Stories View More Recent Stories

May 19, 2020 06:30AM ProMIS Neurosciences and BC Neuroimmunology expand collaboration to develop and commercialize proprietary diagnostic assays
May 13, 2020 06:30AM ProMIS Neurosciences Announces First Quarter 2020 Results
May 12, 2020 06:30AM ProMIS Neurosciences identifies multiple novel targets on SARS CoV-2 for development of a highly accurate COVID-19 antibody test
May 6, 2020 06:30AM ProMIS Neurosciences develops novel antagonists for RACK1, a protein involved in numerous neurodegenerative diseases, including ALS
Apr 30, 2020 06:30AM ProMIS Neurosciences creates novel intrabodies for ALS, frontotemporal dementia and other neurodegenerative diseases
Apr 22, 2020 02:43PM ProMIS Neurosciences commends Biogen for clarifying aducanumab regulatory filing
Apr 15, 2020 06:30AM ProMIS Neurosciences announces collaboration to develop serological test to assess COVID-19 immunity
Apr 9, 2020 06:30AM Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates
Apr 7, 2020 06:30AM ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020
Mar 24, 2020 06:30AM PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING
Mar 18, 2020 06:30AM ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results
Feb 26, 2020 06:30AM ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease
Feb 25, 2020 06:30AM ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants
Feb 11, 2020 06:30AM ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference
Feb 6, 2020 06:30AM ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
Feb 6, 2020 06:30AM ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference
Jan 29, 2020 06:30AM ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020
Jan 15, 2020 06:30AM ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board
Jan 9, 2020 06:30AM ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum
Jan 8, 2020 06:30AM ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020
Dec 31, 2019 01:54PM ProMIS Neurosciences Completes Second Closing of Private Placement
Dec 10, 2019 07:30AM ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news
Dec 5, 2019 12:50PM Aducanumab is good; next generation Alzheimer’s disease therapies will be better
Nov 14, 2019 07:30AM ProMIS Neurosciences Announces Third Quarter 2019 Results
Nov 7, 2019 07:30AM ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease
Oct 24, 2019 03:00AM ProMIS Neurosciences issues Chairman's update memorandum and white paper on Alzheimer's disease
Oct 23, 2019 09:49AM ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
Oct 17, 2019 07:30AM ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau
Oct 8, 2019 07:30AM ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy
Sep 16, 2019 07:30AM ProMIS Neurosciences Executive Chairman Eugene Williams to Speak on Panel at Fall Investor Summit
Sep 3, 2019 07:30AM ProMIS Neurosciences to Present at HC Wainwright Investment Conference
Aug 27, 2019 07:30AM ProMIS Neurosciences Appoints Internationally Recognized Researcher in Alzheimer's Disease in Down Syndrome Dr. Andre Strydom to its Scientific Advisory Board
Aug 13, 2019 07:30AM ProMIS Neurosciences Announces Second Quarter 2019 Results
Jul 18, 2019 03:00PM ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
Jul 10, 2019 07:30AM ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference
Jul 9, 2019 07:30AM ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
Jun 27, 2019 07:30AM ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
Jun 27, 2019 07:30AM ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
Jun 19, 2019 07:30AM ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
Jun 5, 2019 07:30AM ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
May 29, 2019 07:30AM ProMIS Neurosciences' Eugene Williams to Present at JLABS' Conference on Innovations in Neurodegenerative Diseases
May 28, 2019 07:30AM ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer's Disease with Selectivity for the Neurotoxic Form of Tau
May 14, 2019 07:30AM ProMIS Neurosciences Announces First Quarter 2019 Results
Apr 23, 2019 07:30AM ProMIS Neurosciences to Participate in the Think Equity Investor Conference
Mar 26, 2019 07:30AM ProMIS Neurosciences to Participate in Microcap Spring Investor Summit 2019
Mar 21, 2019 02:47PM Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer's Disease
Mar 19, 2019 07:30AM ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson's Disease at AD/PD™ 2019 Conference
Mar 15, 2019 07:30AM ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
Feb 21, 2019 07:30AM ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors
Jan 31, 2019 07:30AM Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease
View More Recent Stories View Older Stories